Skip to main content
SpringerLink
Log in

The Social and Economic Burden of Venous Leg Ulcers

Focus on the Role of Micronized Purified Flavonoid Fraction Adjuvant Therapy

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Chronic venous insufficiency (CVI) occurs in a relatively large proportion of the population and is associated with significant morbidity, high cost of healthcare, loss of productivity and reduced quality of life. Lower extremity ulcers related to CVI have been estimated to affect 0.2–1% of the population in developed countries. The prevalence of venous ulcers in the US is estimated at 500 000–600 000, and increases with age. Estimates of the annual incidence of leg ulcer in the UK and Switzerland are 3.5 and 0.2 per 1000 individuals, respectively. Treatment of venous ulcers can be expensive, leading to a large economic burden on health services in many countries. The annual cost of CVI is estimated to be more than $US1 billion in the US and between £400–600 million in the UK. Current treatments for CVI include surgery, sclerotherapy, compressive therapy (conventional therapy) and adjuvant pharmacotherapy. Various pharmacological agents have been used as adjuvant therapy but in many cases there is no definitive evidence of their efficacy.

Effective treatment programs for venous leg ulcers could substantially reduce the economic impact of CVI on health services. In controlled studies, micronized purified flavonoid fraction (MPFF) adjuvant therapy has been shown to increase significantly the number of healed venous leg ulcers and to reduce significantly the healing time of ulcers compared with conventional therapy alone, potentially leading to an improvement in patients’ quality of life. The treatment of venous leg ulcers with MPFF was also found to reduce overall treatment costs compared with conventional therapy alone. In a retrospective cost-effectiveness analysis based on direct medical costs only, MPFF therapy improved the cost-effectiveness ratio by 45% compared with conventional therapy. If intangible costs, such as loss of quality of life were included, the difference in cost-effectiveness ratios is likely to be even greater in favor of MPFF. Sensitivity analyzes showed that even with a 20% increase in drug price the cost-effectiveness ratio for MPFF therapy was substantially better than that for conventional therapy ($US1061.8 vs 1871.9 per ulcer healed). Hence, the addition of MPFF adjuvant therapy to the treatment of venous leg ulcers would be effective and potentially cost saving.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Table IV
Table V

Similar content being viewed by others

Notes

  1. The use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Valencia IC, Fallabella A, Kirsner RS, et al. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol 2001; 44 (3): 401–21

    Article  PubMed  CAS  Google Scholar 

  2. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Int Angiol 1999; 18: 83–102

    PubMed  CAS  Google Scholar 

  3. Ramelet AA. Clinical benefits of Daflon 500mg in the most severe stages of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: 49–56

    Article  Google Scholar 

  4. De Castro Silva M. Chronic venous insufficiency of the lower limbs and its socio-economic significance. Int Angiol 1991; 10: 152–7

    Google Scholar 

  5. Phillips T, Stanton B, Provan A, et al. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol 1994; 31: 49–53

    Article  PubMed  CAS  Google Scholar 

  6. Franks PJ, Moffatt CJ. Health related quality of life in patients with venous ulceration: use of the Nottingham Health Profile. Qual Life Res 2001; 10: 693–700

    Article  PubMed  CAS  Google Scholar 

  7. Marston WA, Carlin RE, Passman MA, et al. Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. J Vasc Surg 1999; 30: 491–8

    Article  PubMed  CAS  Google Scholar 

  8. Olin JW, Beusterien KM, Childs MB, et al. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med 1999; 4: 1–7

    PubMed  CAS  Google Scholar 

  9. Cornwall JV, Doré CJ, Lewis JD. Leg ulcers: epidemiology and aetiology. Br J Surg 1986; 73: 693–6

    Article  PubMed  CAS  Google Scholar 

  10. Douglas WS, Simpson NB. Guidelines for the management of chronic venous leg ulceration: report of a multidisciplinary workshop. British Association of Dermatologists and the Research Unit of the Royal College of Physicians. Br J Dermatol 1995; 132: 446–52

    Article  PubMed  CAS  Google Scholar 

  11. Nelzen O, Bergqvist D, Lindhagen A, et al. Chronic leg ulcers: an underestimated problem in primary health care among elderly patients. J Epidemiol Community Health 1991; 45: 184–7

    Article  PubMed  CAS  Google Scholar 

  12. Skene AI, Smith JM, Dore CJ, et al. Venous leg ulcers: a prognostic index to predict time to healing. BMJ 1992; 305: 1119–21

    Article  PubMed  CAS  Google Scholar 

  13. Callam MJ, Harper DR, Dale JJ, et al. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed) 1987; 294: 1389–91

    Article  CAS  Google Scholar 

  14. Lévy E, Los F, Chevalier H, et al. The 1999 Venous Disease Survey: epidemiology, management, and patient profiles. Angiology 2001; 52: 195–9

    PubMed  Google Scholar 

  15. Jantet G, RELIEF Study Group. Chronic venous insufficiency: worldwide results of the RELIEF Study. Angiology 2002; 53: 245–56

    Article  Google Scholar 

  16. Nicolaides AN. Investigation of chronic venous insufficiency: a consensus statement. Circulation 2000; 102: E126–63

    Article  Google Scholar 

  17. Laing W. Chronic venous disease of the leg. London: Office of Health Economics, 1992: 1–44

    Google Scholar 

  18. Lévy E, Lévy P. Management of venous leg ulcers by French physicians, diversity and related costs: a prospective and medicoeconomic observational study [in French]. J Mal Vasc 2001; 26: 39–44

    PubMed  Google Scholar 

  19. Simka M. Application of various types of dressings and cost of management of venous ulceration. Abstract book of the 20th World Congress of the International Union of Angiology; 2002 Apr 7–11; New York City: 134

    Google Scholar 

  20. Bosanquet N, Franks P, Moffatt C, et al. Community leg ulcer clinics: cost-effectiveness. Health Trends 1993–1994; 25: 146–8

    PubMed  Google Scholar 

  21. Faresjö T, Frödin T, Vahlquist C, et al. Costs of the treatment of leg ulcers: initiating a quality assurance process. Int J Health Care Qual Assur Inc Leadersh Health Serv 1997; 10: 125–30

    PubMed  Google Scholar 

  22. Morrell CJ, Walters SJ, Dixon S, et al. Cost effectiveness of community leg ulcer clinics: randomised controlled trial. BMJ 1998; 316: 1487–91

    Article  PubMed  CAS  Google Scholar 

  23. Pieper B, Szczepaniak K, Templin T. Psychosocial adjustment, coping, and quality of life in persons with venous ulcers and a history of intravenous drug use. J Wound Ostomy Continence Nurs 2000; 27: 227–37

    PubMed  CAS  Google Scholar 

  24. Bosanquet N, Franks P. Venous disease: the new international challenge. Phlebology 1996; 11: 6–9

    Google Scholar 

  25. McInnes E, Cullum N, Nelson EA, et al. The development of a national guideline on the management of leg ulcers. J Clin Nurs 2000; 9: 208–17

    Article  PubMed  CAS  Google Scholar 

  26. Cresswell J. New guidelines on venous leg ulcer management. Community Nurse 1999; 5: 53–5

    PubMed  CAS  Google Scholar 

  27. Weingarten MS. State-of-the-art treatment of chronic venous disease. Clin Infect Dis 2001; 32: 949–54

    Article  PubMed  CAS  Google Scholar 

  28. The Alexander House Group. Consensus paper on venous leg ulcers. Phlebology 1992; 7: 48–58

    Google Scholar 

  29. Coleridge Smith PD. The drug treatment of chronic venous insufficiency and venous ulceration. In: Gloviczki P, Yao JST, editors. Handbook of venous disorders. 2nd ed. Arnold, London: 2001 Jul

    Google Scholar 

  30. Alguire PC, Mathes BM. Chronic venous insufficiency and venous ulceration. J Gen Intern Med 1997; 12: 374–83

    Article  PubMed  CAS  Google Scholar 

  31. Paquette D, Falanga V. Leg ulcers. Clin Geriatr Med 2002; 18: 77–88

    Article  PubMed  Google Scholar 

  32. Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18: 604–6

    PubMed  CAS  Google Scholar 

  33. Falabella AF, Carson P, Eaglstein WH, et al. The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity. J Am Acad Dermatol 1998; 39: 737–40

    Article  PubMed  CAS  Google Scholar 

  34. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogenic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 1998; 134: 293–300

    Article  PubMed  CAS  Google Scholar 

  35. Arosio E, Ferrari G, Santoro L, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg 2001; 22: 365–72

    Article  PubMed  CAS  Google Scholar 

  36. Bittiner SB. Oxpentifylline treatment of venous leg ulcers. BMJ 1990; 300: 1528

    Article  PubMed  CAS  Google Scholar 

  37. Colgan MP, Dormandy JA, Jones PW, et al. Oxpentifylline treatment of venous ulcers of the leg. BMJ 1990; 300: 972–5

    Article  PubMed  CAS  Google Scholar 

  38. Dale JJ, Ruckley CV, Harper DR, et al. Randomised, double-blind, placebo-controlled trial of pentoxifylline in the treatment of venous leg ulcers. 1999; 319: 875–8

    Google Scholar 

  39. Gajraj H, Jopp-McKay A, Stacey MC. Oxpentifylline treatment of venous leg ulcers [letter]. BMJ 1990; 300: 1725

    Article  PubMed  CAS  Google Scholar 

  40. De Sanctis MT, Belcaro G, Cesarone MR, et al. Treatment of venous ulcers with pentoxifylline: a 12-month, double-blind, placebo controlled trial: microcirculation and healing. Angiology 2002; 53 Suppl. 1: 49–51

    Article  Google Scholar 

  41. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999; 7: 208–13

    Article  PubMed  CAS  Google Scholar 

  42. Jull AB, Waters J, Arroll B. Pentoxifylline for treating venous leg ulcers. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002: CD001733

    Google Scholar 

  43. Struckmann JR. Clinical efficacy of micronised purified flavonoid fraction: an overview. J Vasc Res 1999; 36 Suppl. 1: 37–41

    Article  PubMed  CAS  Google Scholar 

  44. Guilhou J-J, Dereure O, Marzin L, et al. Efficacy of Daflon 500mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology 1997; 48: 77–85

    Article  PubMed  CAS  Google Scholar 

  45. Gliński W, Chodynicka B, Roszkiewicz J, et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology 1999; 14: 151–7

    Article  Google Scholar 

  46. Ibegbuna V, Nicolaides AN, Sowade O, et al. Venous elasticity after treatment with Daflon 500mg. Angiology 1997; 48: 45–9

    Article  PubMed  CAS  Google Scholar 

  47. Bergan JJ, Schmid-Schönbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500mg. Angiology 2001; 52 Suppl. 1: 43–7

    Article  Google Scholar 

  48. Labrid C. Pharmacologic properties of Daflon 500mg. Angiology 1994; 45: 524–30

    PubMed  CAS  Google Scholar 

  49. Garner RC, Garner JV, Gregory S, et al. Comparison of the absorption of micronized (Daflon 500mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci 2002; 91: 32–40

    Article  PubMed  CAS  Google Scholar 

  50. Roztočil K, Štvrtinová V, Strejček J. Efficacy of a 6-month treatment with Daflon 500mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003; 22: 24–31

    PubMed  Google Scholar 

  51. Splawiński J. Cost-effectiveness analysis of micronized purified flavonoid fraction (MPFF) in the treatment of venous ulceration. Medicographia 2000; 22: 157–61

    Google Scholar 

Download references

Acknowledgements

This paper was supported by an educational grant from Servier.

Author information

Authors and Affiliations

  1. Out-Patient Department of Angiology, Pszczyna ul. Wodzislawska, 78-43-200, Pszczyna, Poland

    Marian Simka

  2. Department of General and Vascular Surgery, Silesian Medical Academy, Tychy, Poland

    Eugeniusz Majewski

Authors
  1. Marian Simka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugeniusz Majewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marian Simka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simka, M., Majewski, E. The Social and Economic Burden of Venous Leg Ulcers. Am J Clin Dermatol 4, 573–581 (2003). https://doi.org/10.2165/00128071-200304080-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200304080-00007

Keywords

Search

Navigation